SVB Leerink Equities Analysts Raise Earnings Estimates for Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating) – Analysts at SVB Leerink raised their Q2 2022 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of ($0.50) for the quarter, up from their previous forecast of ($0.51). SVB Leerink also issued estimates for Xenon Pharmaceuticals’ Q3 2022 earnings at ($0.66) EPS, Q4 2022 earnings at ($0.86) EPS, FY2022 earnings at ($2.40) EPS, FY2023 earnings at ($3.05) EPS, FY2024 earnings at ($1.55) EPS and FY2025 earnings at ($0.60) EPS.

Xenon Pharmaceuticals (NASDAQ:XENEGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.10). Xenon Pharmaceuticals had a negative return on equity of 24.14% and a negative net margin of 425.88%. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $4.20 million. During the same quarter in the previous year, the company posted ($0.34) EPS.

Several other research analysts also recently weighed in on XENE. StockNews.com started coverage on shares of Xenon Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating on the stock. TheStreet upgraded shares of Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a report on Monday, March 14th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, March 2nd. Finally, Wedbush reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $44.00.

XENE opened at $32.19 on Monday. The business’s fifty day simple moving average is $31.55. Xenon Pharmaceuticals has a 1-year low of $14.65 and a 1-year high of $36.42. The firm has a market capitalization of $1.67 billion, a P/E ratio of -17.31 and a beta of 1.79.

A number of institutional investors and hedge funds have recently bought and sold shares of XENE. Captrust Financial Advisors bought a new position in Xenon Pharmaceuticals during the third quarter worth about $46,000. Macquarie Group Ltd. boosted its position in Xenon Pharmaceuticals by 551.9% during the third quarter. Macquarie Group Ltd. now owns 3,514 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 2,975 shares during the period. Accel Wealth Management bought a new position in Xenon Pharmaceuticals during the third quarter worth about $60,000. JPMorgan Chase & Co. boosted its position in Xenon Pharmaceuticals by 104.1% during the fourth quarter. JPMorgan Chase & Co. now owns 4,775 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 119,961 shares during the period. Finally, Morgan Stanley boosted its position in Xenon Pharmaceuticals by 101.7% during the first quarter. Morgan Stanley now owns 4,959 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 2,500 shares during the period. Institutional investors own 69.15% of the company’s stock.

In related news, EVP James R. Empfield sold 32,853 shares of the stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $30.54, for a total transaction of $1,003,330.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sherrington Robin sold 21,710 shares of the stock in a transaction dated Friday, March 4th. The shares were sold at an average price of $30.50, for a total transaction of $662,155.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,974 shares of company stock valued at $2,899,047. Company insiders own 7.48% of the company’s stock.

About Xenon Pharmaceuticals (Get Rating)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Featured Stories

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.